LFVN
LifeVantage Corporation NASDAQ Listed Apr 7, 1994$6.00
After hrs
$5.20
-13.28%
Mkt Cap $76.8M
52w Low $3.90
18.9% of range
52w High $15.00
50d MA $4.71
200d MA $7.69
P/E (TTM)
6.8x
EV/EBITDA
9.9x
P/B
1.9x
Debt/Equity
0.3x
ROE
22.8%
P/FCF
15.3x
RSI (14)
—
ATR (14)
—
Beta
0.39
50d MA
$4.71
200d MA
$7.69
Avg Volume
185.1K
About
LifeVantage Corporation engages in the identification, research, development, formulation, sale, and distribution of nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care products, bath and body, and targeted relief products. The company offers Protandim, a line of scientifically validated dietary supplements; LifeVantage Omega+, a di…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 4, 2026 | AMC | 0.19 | 0.15 | -21.1% | 5.55 | -28.5% | -16.8% | -9.4% | -8.6% | -11.2% | -8.3% | — |
| Nov 4, 2025 | AMC | 0.17 | 0.18 | +5.9% | 7.00 | +8.6% | +4.4% | -3.6% | +5.7% | +3.7% | -6.0% | — |
| Sep 4, 2025 | AMC | 0.17 | 0.17 | +0.0% | 13.46 | -19.8% | -10.0% | -15.0% | -12.0% | -16.6% | -12.9% | — |
| May 6, 2025 | AMC | 0.16 | 0.26 | +62.5% | 11.97 | -12.3% | -6.6% | -0.8% | +2.5% | -0.9% | +1.3% | — |
| Feb 5, 2025 | AMC | 0.13 | 0.22 | +69.2% | 22.74 | -25.9% | -16.5% | -15.1% | -8.9% | -13.5% | -14.9% | — |
| Oct 29, 2024 | AMC | 0.15 | 0.15 | +0.0% | 12.98 | -3.6% | -0.4% | -5.9% | +0.2% | +4.0% | +11.2% | — |
| Aug 28, 2024 | AMC | 0.21 | 0.14 | -33.3% | 8.81 | +3.7% | -11.8% | -9.6% | -12.5% | -0.3% | +2.2% | — |
| May 2, 2024 | AMC | 0.16 | 0.21 | +31.2% | 6.11 | -0.8% | +7.5% | +10.8% | +3.8% | +8.7% | +11.3% | — |
| Jan 30, 2024 | AMC | 0.04 | 0.10 | +150.0% | 5.83 | -3.1% | -8.9% | -6.2% | -4.1% | -0.9% | +3.8% | — |
| Nov 9, 2023 | AMC | — | 0.13 | — | 7.27 | -1.0% | -21.7% | -39.8% | -36.0% | -35.5% | -32.7% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 18 | Freedom Broker | Maintains | Buy → Buy | — | $4.94 | $4.93 | -0.2% | -0.2% | +2.4% | -1.8% | -7.1% | -8.3% |
| Nov 14 | Freedom Broker | Maintains | Buy → Buy | — | $6.47 | $6.44 | -0.5% | +2.3% | -2.8% | +0.2% | -1.1% | -2.5% |
| Feb 12 | Imperial Capital | Maintains | In Line → In Line | — | $10.29 | $10.36 | +0.7% | -4.8% | -6.1% | -9.5% | -9.5% | -7.5% |
Recent Filings
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Moorehead's appointment as CEO signals leadership transition at Lifevantage, potentially indicating strategic direction changes that investors should monitor for impact on operational execution and stock performance.
Apr 16
8-K · 5.02
!!! Very High
Lifevantage Corporation Common Stock (Delaware) -- 8-K 5.02: Executive Change
Lifevantage's president and CEO Fife will retire in April 2026 without disagreement, signaling an orderly leadership transition for the nutritional supplement company.
Feb 4
Data updated apr 25, 2026 6:58pm
· Source: massive.com